Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.

Matyskiela ME, Lu G, Ito T, Pagarigan B, Lu CC, Miller K, Fang W, Wang NY, Nguyen D, Houston J, Carmel G, Tran T, Riley M, Nosaka L, Lander GC, Gaidarova S, Xu S, Ruchelman AL, Handa H, Carmichael J, Daniel TO, Cathers BE, Lopez-Girona A, Chamberlain PP.

Nature. 2016 Jul 14;535(7611):252-7. doi: 10.1038/nature18611. Epub 2016 Jun 22.

PMID:
27338790
2.

Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.

Rychak E, Mendy D, Shi T, Ning Y, Leisten J, Lu L, Miller K, Narla RK, Orlowski RZ, Raymon HK, Bjorklund CC, Thakurta A, Gandhi AK, Cathers BE, Chopra R, Daniel TO, Lopez-Girona A.

Br J Haematol. 2016 Mar;172(6):889-901. doi: 10.1111/bjh.13905. Epub 2016 Feb 23.

PMID:
26914976
3.

A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples.

Ren Y, Wang M, Couto S, Hansel DE, Miller K, Lopez-Girona A, Bjorklund CC, Gandhi AK, Thakurta A, Chopra R, Breider M.

Appl Immunohistochem Mol Morphol. 2016 Nov/Dec;24(10):695-702.

4.

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.

Hagner PR, Man HW, Fontanillo C, Wang M, Couto S, Breider M, Bjorklund C, Havens CG, Lu G, Rychak E, Raymon H, Narla RK, Barnes L, Khambatta G, Chiu H, Kosek J, Kang J, Amantangelo MD, Waldman M, Lopez-Girona A, Cai T, Pourdehnad M, Trotter M, Daniel TO, Schafer PH, Klippel A, Thakurta A, Chopra R, Gandhi AK.

Blood. 2015 Aug 6;126(6):779-89. doi: 10.1182/blood-2015-02-628669. Epub 2015 May 22.

5.

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.

Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B, Rychak E, Corral LG, Ren YJ, Wang M, Riley M, Delker SL, Ito T, Ando H, Mori T, Hirano Y, Handa H, Hakoshima T, Daniel TO, Cathers BE.

Nat Struct Mol Biol. 2014 Sep;21(9):803-9. doi: 10.1038/nsmb.2874. Epub 2014 Aug 10.

PMID:
25108355
6.

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.

Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, Cathers B, Schwaederlé M, Cui B, Lopez-Girona A, Messmer D, Kipps TJ.

Blood. 2014 Sep 4;124(10):1637-44. doi: 10.1182/blood-2014-03-559591. Epub 2014 Jul 2.

7.

Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.

Chen X, Díaz-Rodríguez E, Ocio EM, Paiva B, Mortensen DS, Lopez-Girona A, Chopra R, Miguel JS, Pandiella A.

Mol Cancer Ther. 2014 Feb;13(2):504-16. doi: 10.1158/1535-7163.MCT-13-0022. Epub 2014 Jan 15.

8.

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.

Gandhi AK, Mendy D, Waldman M, Chen G, Rychak E, Miller K, Gaidarova S, Ren Y, Wang M, Breider M, Carmel G, Mahmoudi A, Jackson P, Abbasian M, Cathers BE, Schafer PH, Daniel TO, Lopez-Girona A, Thakurta A, Chopra R.

Br J Haematol. 2014 Jan;164(2):233-44. doi: 10.1111/bjh.12622. Epub 2013 Oct 28.

9.

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy.

Thakurta A, Gandhi AK, Waldman MF, Bjorklund C, Ning Y, Mendy D, Schafer P, Lopez-Girona A, Lentzsch S, Schey SA, Calle Y, Chelliah R, Orlowski RZ, Madan A, Avet-Loiseau H, Chopra R.

Leukemia. 2014 May;28(5):1129-31. doi: 10.1038/leu.2013.315. Epub 2013 Oct 29. No abstract available.

10.

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.

Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R.

Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub 2012 May 3. Erratum in: Leukemia. 2012 Nov;26(11):2445.

11.

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.

Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H, Bartlett JB, Schafer PH, Schreder M, Bolomsky A, Hilgarth B, Zojer N, Gisslinger H, Ludwig H, Daniel T, Jäger U, Chopra R.

Br J Haematol. 2011 Aug;154(3):325-36. doi: 10.1111/j.1365-2141.2011.08689.x. Epub 2011 Jun 24.

PMID:
21707574
12.

An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme.

Ceccarelli DF, Tang X, Pelletier B, Orlicky S, Xie W, Plantevin V, Neculai D, Chou YC, Ogunjimi A, Al-Hakim A, Varelas X, Koszela J, Wasney GA, Vedadi M, Dhe-Paganon S, Cox S, Xu S, Lopez-Girona A, Mercurio F, Wrana J, Durocher D, Meloche S, Webb DR, Tyers M, Sicheri F.

Cell. 2011 Jun 24;145(7):1075-87. doi: 10.1016/j.cell.2011.05.039. Epub 2011 Jun 16.

13.

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.

Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinoso L, Fang W, Xu S, Hampton G, Bartlett JB, Schafer P.

Curr Cancer Drug Targets. 2010 Mar;10(2):155-67.

PMID:
20088798
14.

Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases.

Xu Y, Li J, Ferguson GD, Mercurio F, Khambatta G, Morrison L, Lopez-Girona A, Corral LG, Webb DR, Bennett BL, Xie W.

Blood. 2009 Jul 9;114(2):338-45. doi: 10.1182/blood-2009-02-200543. Epub 2009 May 5.

PMID:
19417207
15.

Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.

Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ.

Blood. 2008 May 1;111(9):4690-9. doi: 10.1182/blood-2007-09-112904. Epub 2008 Feb 27.

16.

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.

Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K, Schafer PH, Chen R, Glezer E, Ferguson GD, Lopez-Girona A, Muller GW, Brady HA, Chan KW.

Cancer Res. 2007 Jan 15;67(2):746-55.

17.

Replication checkpoint kinase Cds1 regulates recombinational repair protein Rad60.

Boddy MN, Shanahan P, McDonald WH, Lopez-Girona A, Noguchi E, Yates III JR, Russell P.

Mol Cell Biol. 2003 Aug;23(16):5939-46.

18.

DNA damage checkpoint control of mitosis in fission yeast.

Rhind N, Baber-Furnari BA, Lopez-Girona A, Boddy MN, Brondello JM, Moser B, Shanahan P, Blasina A, McGowan C, Russell P.

Cold Spring Harb Symp Quant Biol. 2000;65:353-9. Review. No abstract available.

PMID:
12760050
19.

Serine-345 is required for Rad3-dependent phosphorylation and function of checkpoint kinase Chk1 in fission yeast.

Lopez-Girona A, Tanaka K, Chen XB, Baber BA, McGowan CH, Russell P.

Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11289-94. Epub 2001 Sep 11.

20.

Nuclear exclusion of Cdc25 is not required for the DNA damage checkpoint in fission yeast.

Lopez-Girona A, Kanoh J, Russell P.

Curr Biol. 2001 Jan 9;11(1):50-4.

21.

Damage tolerance protein Mus81 associates with the FHA1 domain of checkpoint kinase Cds1.

Boddy MN, Lopez-Girona A, Shanahan P, Interthal H, Heyer WD, Russell P.

Mol Cell Biol. 2000 Dec;20(23):8758-66.

22.

Regulation of mitotic inhibitor Mik1 helps to enforce the DNA damage checkpoint.

Baber-Furnari BA, Rhind N, Boddy MN, Shanahan P, Lopez-Girona A, Russell P.

Mol Biol Cell. 2000 Jan;11(1):1-11.

23.

Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein.

Lopez-Girona A, Furnari B, Mondesert O, Russell P.

Nature. 1999 Jan 14;397(6715):172-5.

PMID:
9923681
24.

Calmodulin is essential for cyclin-dependent kinase 4 (Cdk4) activity and nuclear accumulation of cyclin D1-Cdk4 during G1.

Taulés M, Rius E, Talaya D, López-Girona A, Bachs O, Agell N.

J Biol Chem. 1998 Dec 11;273(50):33279-86.

25.

Negative regulation of Cdc18 DNA replication protein by Cdc2.

Lopez-Girona A, Mondesert O, Leatherwood J, Russell P.

Mol Biol Cell. 1998 Jan;9(1):63-73.

26.

Interaction of Cdc2 and Cdc18 with a fission yeast ORC2-like protein.

Leatherwood J, Lopez-Girona A, Russell P.

Nature. 1996 Jan 25;379(6563):360-3.

PMID:
8552194
27.

Calmodulin is involved in the induction of DNA polymerases alpha and delta activities in normal rat kidney cells activated to proliferate.

López-Girona A, Bachs O, Agell N.

Biochem Biophys Res Commun. 1995 Dec 14;217(2):566-74.

PMID:
7503737
28.

Addition of calmodulin antagonists to NRK cells during G1 inhibits proliferating cell nuclear antigen expression.

López-Girona A, Bosch M, Bachs O, Agell N.

Cell Calcium. 1995 Jul;18(1):30-40.

PMID:
7585881
29.

Protein kinase C regulates calmodulin expression in NRK cells activated to proliferate from quiescence.

Bosch M, López-Girona A, Bachs O, Agell N.

Cell Calcium. 1994 Dec;16(6):446-54.

PMID:
7712538
30.

Calmodulin expression during rat liver regeneration.

Agell N, Pujol MJ, López-Girona A, Bosch M, Rosa JL, Bachs O.

Hepatology. 1994 Oct;20(4 Pt 1):1002-8.

PMID:
7927201
31.

Calmodulin regulates the expression of cdks, cyclins and replicative enzymes during proliferative activation of human T lymphocytes.

Colomer J, López-Girona A, Agell N, Bachs O.

Biochem Biophys Res Commun. 1994 Apr 15;200(1):306-12.

PMID:
7909433
32.

Calmodulin regulates DNA polymerase alpha activity during proliferative activation of NRK cells.

López-Girona A, Colomer J, Pujol MJ, Bachs O, Agell N.

Biochem Biophys Res Commun. 1992 May 15;184(3):1517-23.

PMID:
1590809

Supplemental Content

Loading ...
Support Center